Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 22NIH 9NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 21Lymphoma 10Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 2Recurrence 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Stomach Neoplasms 1Sezary Syndrome 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 4Cyclophosphamide 4Vincristine 3Rituximab 3Prednisone 3Dexamethasone 3Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Interferon-alpha 2Etoposide 2Cytarabine 2Bortezomib 2tositumomab I-131 1liposomal amphotericin B 1fludarabine 1denileukin diftitox 1Watchful Waiting 1Vancomycin 1VAP-cyclo protocol 1Thalidomide 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Palliative Care 1Nutritional Support 1Moxifloxacin 1Morphine 1Methotrexate 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Waldenstrom Macroglobulinemia × Bortezomib × Clear all
NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT00832234 2015-02-18

BDR-WM

European Myeloma Network B.V.

Phase 2 Completed
59 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡